M Morimoto1, S Shimakawa1, T Hashimoto1, T Kitaoka2, S Kyotani2. 1. Japanese Red Cross Tokushima Hinomine Rehabilitation Center for People with Disabilities, Tokushima, Japan. 2. Graduate School of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan.
Abstract
WHAT IS KNOWN AND OBJECTIVE: Dravet syndrome (DS) is an intractable epilepsy syndrome. The three-drug combination therapy of sodium valproate (VPA), clobazam (CLB) and stiripentol (STP) is recommended worldwide. CASE SUMMARY: We present a case of DS, in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate (TPM) proved to be markedly effective. WHAT IS NEW AND CONCLUSION: It is suggested that combination therapy with VPA, TPM and STP is for DS epilepsy.
WHAT IS KNOWN AND OBJECTIVE:Dravet syndrome (DS) is an intractable epilepsy syndrome. The three-drug combination therapy of sodium valproate (VPA), clobazam (CLB) and stiripentol (STP) is recommended worldwide. CASE SUMMARY: We present a case of DS, in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate (TPM) proved to be markedly effective. WHAT IS NEW AND CONCLUSION: It is suggested that combination therapy with VPA, TPM and STP is for DS epilepsy.
Authors: Natalie Ann Lozano-Huntelman; April Zhou; Elif Tekin; Mauricio Cruz-Loya; Bjørn Østman; Sada Boyd; Van M Savage; Pamela Yeh Journal: iScience Date: 2021-03-26
Authors: Chelsea D Pernici; Jeffrey A Mensah; E Jill Dahle; Kristina J Johnson; Laura Handy; Lauren Buxton; Misty D Smith; Peter J West; Cameron S Metcalf; Karen S Wilcox Journal: Epilepsia Date: 2021-05-17 Impact factor: 6.740